comparemela.com

Latest Breaking News On - Bradley canino - Page 5 : comparemela.com

Biotech ETFs Strengthen as Bristol Myers Squibb Buys Turning Point

Biotechnology sector-related exchange traded funds were a bright spot on Friday after Bristol Myers Squibb Co. (NYSE: BMY) said it will acquire drug developers Turning Point Therapeutics (NasdaqGS: TPTX).

Bradley caninoGiovanni caforioBristol myersPoint therapeutics incBristol myers squibbBristol myers squibb coTurning point therapeuticsVirtus lifesci biotech clinical trialsTurning point therapeutics incTurning pointXchange traded fundsStock marketState street

Bristol Myers Boosts Cancer Drug Portfolio With $4.1 Billion Turning Point Deal

Bristol Myers Squibb Co. said on Friday it will acquire drug developer Turning Point Therapeutics Inc. for $4.1 .

Bristol myer opdivoBristol myerBradley caninoBristol myersMerck co incPoint therapeutics incBristol myers squibb coBristol myers squibbTurning point therapeuticsTurning pointCancer drugThe epoch times

Bristol Myers bets $4B on Turning Point and its targeted cancer drugs

BioPharma

Roche rozlytrekBristol myerBradley caninoBayer vitrakviEli lillyBristol myersDrug administrationBristol myers squibbDive briefMyers squibbTurning point therapeuticsTurning pointLoxo oncologyBlueprint medicinesBlack diamond therapeutics

vimarsana © 2020. All Rights Reserved.